公司资料
Kazia Therapeutics Limited 股价、新闻与催化剂
- 股票代码:
- KZIA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Australia and listed in the U
股票表现
13.56 USD (+0.30%)
收盘价
最后更新: 2026年8月17日
135M USD
市值
股价为何变动
As of Aug 17, 2026, KZIA closed up 0.30% at $13.56. No new same-company headline was identified in the current news window.
公司概览
业务概览
Kazia Therapeutics is an oncology biotechnology company focused on targeted cancer therapies, including programs aimed at difficult solid tumors and brain tumors. Its story is built around trying to create meaningful value from a specialized oncology pipeline.
所在地与行业分类
Kazia is headquartered in Australia and listed in the U.S. market. It sits in small-cap oncology biotechnology.
商业模式特征
The company depends on clinical data, translational confidence, and the ability to fund a narrow cancer pipeline. Investors usually watch proof-of-concept work and strategic changes.
生物医药行业定位
Kazia occupies a specialized oncology niche within biotech. It is highly catalyst-sensitive because the company is still proving whether the platform can matter clinically.
未来催化剂
- Kazia’s catalysts are paxalisib and the oncology / brain-cancer program, where the next update can materially change the market’s view. The stock remains very much a data story.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。